Combination of fractional CO laser with PRP injection is a promising treatment for vitiligo, followed by combination of fractional CO laser with NB-UVB phototherapy. Both fractional CO laser and PRP injection gave poor results if they received alone.

Background: Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL). Differentiation of MF especially early stages (eMF) from its benign mimickers is important to ensure proper management. TOX is a critical regulator of early T-cell development in the thymus that is considered as a useful marker for MF diagnosis and prognosis. Objective: The aim of the current study was to evaluate the ability of molecular marker TOX protein in diagnosis of eMF, and its ability to differentiate eMF from similar benign inflammatory skin diseases (BIDs). Methodology: This is a case control study and was carried out on 60 subjects; 20 patients as eMF, 20 patients as (BIDs) and 20 normal skin specimens as control cases. The diagnosis was established after clinicopathological correlation. Immunohistochemistry (IHC) was done for MF, BIDs and normal skin cases for TOX and CD4 IHC stains. Results: TOX expression showed a significant positive expression in MF cases compared to BIDs and control groups, with 100% sensitivity and 95% specificity. The pattern of TOX IHC stain in MF was diffuse, while in BIDs was focal. Conclusion: TOX might be considered a diagnostic marker for eMF that can differentiate eMF from BIDs mimickers.

Alopecia areata (AA) is a common cause of non-cicatricial hair loss that presents in a patchy, confluent, or diffuse pattern. It may affect some or all areas of the body, especially the scalp. 1 Severe and recurrent cases of AA can disturb quality of life of patients and may also lead to depression, changed self-image, and interferes with social activities. 2 AA represents an inflammatory disease affecting the hair follicles with a possible multifactorial origin, most prominently with autoimmune and genetic factors. 3 Multiple therapeutic modalities for AA have been reported including immunosuppressive treatments as corticosteroids (topical, intralesional, systemic), photochemotherapy, immunomodulatory treatments as siphenylcyclopropenone, and other treatment options as Anthralin or Minoxidil. 4 AA continues to be a challenging disease, with less than 20% of patients obtaining complete long-term hair regrowth. 5

No abstract

No abstract